Tg Therapeutics (TGTX) Non-Current Assets (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Non-Current Assets of $441.9 million for Q1 2026, up 3528.11% year-over-year from $12.2 million in Q1 2025, and up 2.17% quarter-over-quarter from $432.5 million in Q4 2025.
Tg Therapeutics (TGTX) Non-Current Assets (2010 - 2026) Analysis & Trends
Tg Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $441.9 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 3528.11% year-over-year to $441.9 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 2716.69% YoY), while the FY2025 annual figure was $432.5 million, up 3716.87% from the prior year.
- Non-Current Assets for Q1 2026 stood at $441.9 million, up from $432.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $441.9 million in Q1 2026, with the low at $11.3 million in Q4 2024.
- The 5-year median for Non-Current Assets is $12.7 million (2024), against an average of $95.1 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets slumped 79.32% in 2023, then jumped 3716.87% in 2025.
- Tg Therapeutics' Non-Current Assets stood at $25.3 million in 2022, then sank by 53.97% to $11.6 million in 2023, then decreased by 2.69% to $11.3 million in 2024, then surged by 3716.87% to $432.5 million in 2025, then gained by 2.17% to $441.9 million in 2026.
- Business Quant data shows TGTX's Non-Current Assets at $441.9 million in Q1 2026, $432.5 million in Q4 2025, and $425.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 493.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 493.94 Mn |
| Mar 31, 2026 | 441.87 Mn |
| Dec 31, 2025 | 432.49 Mn |
| Sep 30, 2025 | 425.26 Mn |
| Jun 30, 2025 | 38.65 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Dec 31, 2024 | 11.33 Mn |
| Sep 30, 2024 | 11.95 Mn |
| Jun 30, 2024 | 12.06 Mn |
| Mar 31, 2024 | 12.74 Mn |
| Dec 31, 2023 | 11.64 Mn |
| Sep 30, 2023 | 11.95 Mn |
| Jun 30, 2023 | 12.28 Mn |
| Mar 31, 2023 | 12.58 Mn |
| Dec 31, 2022 | 25.30 Mn |
| Sep 30, 2022 | 34.97 Mn |
| Jun 30, 2022 | 49.11 Mn |
| Mar 31, 2022 | 60.81 Mn |
| Dec 31, 2021 | 48.66 Mn |
| Sep 30, 2021 | 37.91 Mn |